drugset
drugset / Trial / NCT04469920

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

NCT04469920 ↗

Phase 1 Completed 98 enrolled Zydus Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function

Timeline

Start
2020-07-16
Primary completion
2022-03-21
Completion
2022-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Saroglitazar Small molecule 2 mg —
Subject Saroglitazar Small molecule 4 mg —

Indications

No indication recorded.